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The  early  steps  of  HIV-1  infection  starting  after virus  entry  into  cells  up  to  integration  of  its  genome  into
host  chromosomes  are  poorly  understood.  From  seminal  work  showing  that  HIV-1  and  oncoretroviruses
follow  different  steps  in  the  early  stages  post-entry,  signiﬁcant  advances  have  been  made  in recent  years
and an  important  role  for the  HIV-1  capsid  (CA)  protein,  the  constituent  of  the  viral  core,  has  emerged.
CA  appears  to  orchestrate  several  events,  such  as  virus  uncoating,  recognition  by restriction  factors  and
the innate  immune  system.  It  also  plays  a role in  nuclear  import  and  integration  of HIV-1  and  has  become
a  novel  target  for  antiretroviral  drugs.  Here  we  describe  the  different  functions  of CA  and  how  they  mayIV-1
apsid
yclophilin
ncoating
uclear import
ntegration
be integrated  into  one  or  more  coherent  models  that  illuminate  the  early  events  in  HIV-1 infection  and
their  relations  with  the  host  cell.
© 2012 Elsevier B.V. Open access under CC BY license.npo3
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. Introduction
Human immunodeﬁciency virus type 1 (HIV-1) is the causative
gent of AIDS or acquired immunodeﬁciency syndrome. It is a
entivirus uniquely adapted to replicate in human cells, in partic-
lar CD4+ cells such as helper T-lymphocytes, macrophages and
and microglial cells, whereas the CXCR4 co-receptor is mainly
expressed in naïve CD4+ T-cells (Freed and Martin, 2001).
The HIV-1 genome in its integrated DNA form is approximately
9.8 Kb in size and encodes for three polyproteins (Gag, Gag–Pol
and Env) and six smaller accessory proteins (Vif, Vpr, Vpu, Tat, Rev
and Nef). Env mRNA is spliced and translated into gp160, whichicroglial cells. HIV-1 tropism depends mainly on the expression
f the cell receptor CD4 and co-receptors CCR5 and CXCR4. The
even-transmembrane domain chemokine receptor CCR5 is mainly
resent on the surface of memory CD4+ T-cells, macrophages
Abbreviations: CA, capsid protein; CsA, cyclosporine; CypA, cyclophilin A; CPSF6,
leavage and polyadenylation speciﬁcity factor subunit 6; Tnpo3, transportin 3.
∗ Tel.: +44 20 31082138; fax: +44 20 31082123.
E-mail address: a.fassati@ucl.ac.uk
168-1702/     © 2012 Elsevier B.V.  
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Open access under CC BY license.is then cleaved by a furin-like cellular protease into a “surface”
(SU also called gp120) and a “transmembrane” region (TR also
called gp41). Gp120 is responsible for engaging with CD4 and
the co-receptors, whereas gp41 induces fusion of the viral mem-
brane with the cell membrane. Pol encodes for the viral enzymes
protease (PR), reverse transcriptase (RT) and integrase (IN). Gag
encodes for structural proteins matrix (p17 MA), capsid (p24
CA), nucleocapsid (p7 NC), p6 and spacer peptides Sp1 and Sp2
(Freed and Martin, 2001). Gag forms the capsid core and during or
shortly after budding the viral protease cleaves it into the different
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omponents inducing dramatic conformational rearrangements
hat have important functional consequences (Bharat et al., 2012).
In the unprocessed form, Gag polyproteins form a capsid core
f approximately 100 nm diameter with a regular arrangement
hereby p17 MA  is at the outer region in direct contact with the
iral membrane, followed by p24 CA and NC, which is central and
ontacts the viral RNA genome (Bharat et al., 2012; Briggs and
rausslich, 2011; Yeager et al., 1998). Following protease activation
nd Gag cleavage, the immature core undergoes a dramatic rear-
angement resulting in a fullerene conical structure of 100–120 nm
n length and 50–60 nm wide composed of approximately 250 CA
exameric rings organized in a lattice (Fig. 1) (Briggs et al., 2003;
anser et al., 1999; Ganser-Pornillos et al., 2007). Importantly, the
resence of 12 CA pentamers distributed at the edges of the cone, 7
t the wide end and 5 and the narrow end, allows the lattice to
urve and assume the typical conical geometry (Pornillos et al.,
011). The CA subunit within the hexameric ring are stabilized
y quite extensive N-terminal domain (NTD)–NTD intermolecular
nteractions and less extensive NTD–CTD intermolecular interac-
ions, mainly between NTD helices 4 and 7 and CTD helices 8 and
1, whereas adjacent rings are linked together mainly by mobile C-
erminal domain (CTD)–CTD intermolecular interactions (Pornillos
t al., 2009) (Fig. 1). The mobility of the CTD–CTD interactions
llows the formation of the curvature in the lattice (Pornillos et al.,
009). Some details of how the conical geometry is generated are
till unknown because high resolution X-ray crystallography can-
ot be applied to an intact core.
CA forms the building block of the hemaxers in the lattice. It is
 24 kDa protein with independently folded NTD and a CTD that
re ﬂexibly linked (Berthet-Colominas et al., 1999; Gamble et al.,
997; Gitti et al., 1996; Momany et al., 1996). The structure is highly
elical; the NTD contains 7 alpha helices and the CTD contains 4
Gamble et al., 1997; Gitti et al., 1996). Furthermore CA has a large
oop encompassing residues 85–93 between helices 4 and 5 that
s exposed to the surface of the hexamer and binds cyclophilin A
CypA) (Gamble et al., 1996) (Fig. 2).
There are approximately 1500 CA monomers in a mature HIV-
 core but there appears to be an excess of Gag molecules in the
mmature core (up to 5000) (Briggs et al., 2004). Upon Gag cleav-
ge, some CA molecules are not incorporated into the mature core
ut the function of the excess CA is not known (Briggs et al., 2004).
he mature retroviral core is less stable than the immature form
nd it has been difﬁcult to isolate intact HIV-1 cores to perform
iochemical and genetic studies. However it is possible to purify
mall amounts of mature HIV-1 cores by sedimentation in sucrose
radients through a thin layer of mild detergent, which strips the
nvelope and matrix (Aiken, 2009). Alternatively, many aspects of
he core structure and function can be studied in vitro upon for-
ation of the so-called “tubes”. These structures are generated by
ncubating puriﬁed recombinant CA or CA–NC with short RNAs or
ingle stranded DNA oligonucleotides in the appropriate salt con-
itions (Ganser et al., 1999; Gross et al., 1998). The introduction of
he point mutation R18A in CA helps generating lattices of different
eometry, including spheres, cones and cylinders, which recapitu-
ate the bonaﬁde core structure (Ganser-Pornillos et al., 2007).
. CA, core uncoating and reverse transcription
Following cell-receptor mediated entry, HIV-1 starts reverse
ranscribing its RNA genome. An early function of HIV-1 CA is to
rovide a suitable environment for reverse transcription within
he so-called reverse transcription complex (RTC). The virus must
lso shed its core or “uncoat” to progress through the various
teps of the life cycle. We  have an incomplete understanding of
hese early steps, however some progress has been made in recent 170 (2012) 15– 24
years. Biochemical fractionation in sucrose gradients of the cyto-
sol of acutely infected cells indicated that uncoating happens quite
early post-infection, probably within 1 h in the case of HIV-1 but
only after nuclear entry following mitosis in the case of murine
leukemia virus (MLV) (Fassati and Goff, 1999, 2001; Karageorgos
et al., 1993). Notably, the results of the biochemical fractionation
used to characterize MLV  RTCs have been recently conﬁrmed using
a combination of elegant imaging and genetic approaches (Prizan-
Ravid et al., 2010). Because the same fractionation procedure was
used to characterize both viruses, the simplest explanation for the
different time of uncoating of HIV-1 and MLV  is that the MLV  core
is more stable than the HIV-1 core in the cytoplasm of infected
cells. This also explains, at least in part, why  MLV  cannot infect
non dividing cells, given that large amounts of CA are still associ-
ated with its RTC and pre-integration complex (PIC), presumably
making it too bulky to go across nuclear pores (NPCs) (Bowerman
et al., 1989; Fassati and Goff, 1999). The instability of the HIV-1
core as determined in biochemical assays may  be less pronounced
in the cytoplasm of infected cells, where host factors could stabilize
it. However recent genetic evidence supports the idea that HIV-1
uncoating happens as early as 30–45 min  post-infection (Hulme
et al., 2011; Perez-Caballero et al., 2005). In fact the time of uncoat-
ing seems to be cell-type dependent, faster in HeLa cells, slower in
CD4+ T-lymphocytes, suggesting that host cells factors may play a
role as well (Arﬁ et al., 2009). There is evidence supporting the idea
that signiﬁcant uncoating happens before reverse transcription is
completed. APOBEC3G is a restriction factor for HIV-1, counteracted
by the viral accessory protein Vif, that promotes G to A mutations by
deaminating C to U on the negative sense, single stranded viral DNA
generated during reverse transcription (Malim, 2009). Recently, it
has been shown that APOBEC3G in the target cells can attack the
incoming virus in macrophages, suggesting that the protein has
access to the viral genome before the completion of reverse tran-
scription (Koning et al., 2011). LEDGF/p75 is a host co-factor that
binds to HIV-1 IN and stimulates targeted integration into the host
genome (Engelman and Cherepanov, 2008). A dominant form of
LEDGF/p75 that localizes exclusively in the cytoplasm can target IN
and perturb integration, suggesting that IN is accessible within the
RTC/PIC (Meehan et al., 2011). Several host cell factors have been
implicated in promoting reverse transcription, including nucleic
acids binding proteins, DNA repair and splicing factors (Konig et al.,
2008) and it is not unreasonable to assume that at least some of
them act in the target cells on the incoming RTC, which must there-
fore be accessible. More recent data demonstrates that uncoating
and reverse transcription proceed in parallel and may  inﬂuence
each other (Arﬁ et al., 2009; Hulme et al., 2011). It also not clear
how much CA is shed from the core in the cytoplasm. Biochem-
ical studies found that most CA is shed from the HIV-1 RTC and
PIC (Bukrinsky et al., 1993; Farnet and Haseltine, 1991; Fassati and
Goff, 2001; Karageorgos et al., 1993; Miller et al., 1997), yet it is
quite possible that host factors compensate in part for the intrinsic
instability of the HIV-1 core inside cells and that in fact more CA
remains associated with the RTC than previously thought.
If uncoating happens too quickly however, reverse transcription
does not take place. This is supported by two  lines of evidence.
TRIM5 is a restriction factor that blocks HIV-1 infection by
targeting the incoming capsid core and inducing its proteasomal
degradation (Malim and Bieniasz, 2012). TRIM5 acts very early
post-infection (<1 h) and causes premature uncoating, leading
to aborted reverse transcription (Malim and Bieniasz, 2012; Roa
et al., 2012; Stremlau et al., 2006). Second, mutations in CA that
make the HIV-1 core unstable also cause premature uncoating
and aborted reverse transcription (Forshey et al., 2002). In fact
there is elegant work based on speciﬁc mutations in CA and their
functional characterization showing that optimal stability of the
HIV-1 core is important for reverse transcription and for later
A. Fassati / Virus Research 170 (2012) 15– 24 17
Fig. 1. Structure of the HIV-1 core and the CA hexameric lattice. (A) Stereo view of a backbone-only fullerene cone model composed of 1056 CA subunits. The hexamers,
pentamers and dimers are coloured in orange, yellow and blue, respectively. Reprinted from Pornillos et al. (2011) page 426 by permission from McMillan Publishers Ltd.
(B)  Top view of one sheet in the templated CA crystals, which recapitulates the hexameric lattice of authentic capsids at its planar limit. The NTDs are colored orange, and
the  CTDs are blue. Interactions between neighboring hexamers are mediated only by the CTD. Right hand box, top view of the CTD–CTD interface that connects neighboring
hexamers. The black oval represents the twofold symmetry axis. Reprinted from Pornillos et al. (2009) page 1282 with permission from Elsevier. (C) Polar and water-mediated
intermolecular CA contacts within a hexamer. Selected side chains are shown and labeled. Green mesh shows unbiased FO-FC density contoured at +3 s. These were modeled
as  water molecules (magenta spheres) in the structure derived from hexagonal crystals. Putative hydrogen bonds are represented by yellow lines. Reprinted from Pornillos
et  al. (2009) page 1286 with permission from Elsevier.
18 A. Fassati / Virus Research 170 (2012) 15– 24
Fig. 2. Structure of the CA protein. (A) Side view of the pseudoatomic monomer model of full-length CA, with the secondary structural elements labeled, including the
cypA-binding loop. The carboxy terminus of the NTD and amino terminus of the CTD (approximately 4 A˚ apart) are indicated by yellow asterisks. (B) Slabbed side view of
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eprinted from Ganser-Pornillos et al. (2007) page 131 with permission from Elsev
vents, including nuclear transport and integration (Dismuke and
iken, 2006; Forshey et al., 2002; Yamashita et al., 2007). Therefore
t appears that the viral core must remain more or less intact for a
hort period of time, presumably to allow the early steps of reverse
ranscription (Roa et al., 2012).
If signiﬁcant amounts of CA molecules are shed during reverse
ranscription, how are the various components of the RTC kept
ogether in a suitable structure where DNA synthesis can take
lace? Recently it has been shown that eukaryotic elongation fac-
ors 1A and 1G (EIF1A and EIF1G) associate with RT and IN and may
tabilize the RTC, stimulating the late steps of reverse transcrip-
ion (Warren et al., 2012). The same report and a separate globalaffect core assembly. Note the position of the cypA binding loop facing outwards.
proteomics analysis of host factors interacting with HIV-1 proteins
identiﬁed several EIF3 family members that bind to Pol (Jager et al.,
2012; Warren et al., 2012), although in the case of EIF3D the bind-
ing resulted in inhibition of reverse transcription, and in a different
study overexpression of EIF3F or its truncated form was shown to
interfere with viral mRNA production (Jager et al., 2012; Valente
et al., 2009).
Uncoating can also occur at a later stage, once reverse tran-
scription is completed. For example, one electron microscopy study
detected intact cores several hours post-infection and presum-
ably those cores had completed DNA synthesis (Arhel et al., 2007).
Indeed the synthesis of the so-called central polypurine tract (cPPT)
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a triple DNA strand being synthesized late during reverse tran-
cription) appeared to stimulate uncoating (Arhel et al., 2007),
lthough there is controversy on the precise role of the cPPT in HIV-
 infection (Fassati, 2006). Similar to the biochemical approaches,
maging approaches also suffer from the caveat that it is often
nclear which form of the RTC is functional, particularly when cells
ave been infected at very high multiplicity of infection (MOI). It is
herefore important to combine multiple approaches or perform
omparative analyses of different viruses and selected mutants
hen studying retroviral uncoating (Arhel, 2010; Hulme et al.,
011).
It is presently unclear where uncoating takes place within cells;
ome evidence suggests it occurs in the cytoplasm (Hulme et al.,
011; McDonald et al., 2002), other evidence suggests at NPCs
Arhel et al., 2007). Presumably it can happen in both compartments
nd the question is what selective advantage the virus can gain
y uncoating in one cellular location relative to another. Uncoat-
ng at the NPC might reduce exposure of the viral RNA/DNA to the
ytosolic environment and hence reduce the chances of its degrada-
ion. Yet puriﬁed RTCs containing little CA appear to be resistant to
uclease attack (Fassati and Goff, 2001; Nermut and Fassati, 2003),
uggesting that the virus has evolved ways to protect its genome in
he cytoplasm of infected cells. Another possibility is that a shorter
xposure to the cytosolic environment by uncoating at the NPC
ay  lessen the risk of activation of the innate immunity pathways
ensing cytosolic RNAs or DNAs (Schaller et al., 2011). Although
his idea is attractive, it does not explain why the majority of RTCs
hat uncoat in the cytoplasm fail to activate the innate immune
esponse. On the other hand, a rapid loss of CA and core disassem-
ly may  in fact protect the virus from recognition by the innate
mmune system and restriction factors that target CA (Pertel et al.,
011; Towers et al., 2003).
Therefore the role of CA in these early events is critical. It facil-
tates reverse transcription by controlling core stability, it may
e important to modulate recognition by the innate and intrinsic
mmune system and to recruit important host cell factors, such as
ypA.
. CA and CypA
To my  knowledge, the ﬁrst indirect evidence that CypA was
nvolved in HIV-1 infection was published in 1988 by Wainberg
t al.,  who showed that the drug cyclosporine A (CsA), a com-
ound that binds to CypA and has potent immunosuppressive
ctivity, prevented acute HIV-1 infection. Interestingly, the authors
ade the following observations. First, CsA acted on the early
teps of infection. Second, chronically infected cells were not sen-
itive to the drug. Third, CsA was more active in CD4+ T-cells than
acrophages. Although the authors interpreted the effects of CsA
s inhibition of viral entry, they provided an important seminal
bservation.
The ﬁrst demonstration that CypA and CypB bind to the CA
egion within HIV-1 Gag was provided by Luban et al. (1993)
sing a yeast two hybrid screen and shortly afterwards CypA was
ound to be speciﬁcally incorporated into HIV-1 but not in simian
mmunodeﬁciency virus (SIVmac) and to be important for infection
Franke et al., 1994; Thali et al., 1994). More recent data indicate
hat the interaction between CA and CypA is widespread among
entiviruses, with the exception of SIVmac, and in fact probably pre-
ates HIV by 12 million years, arguing in favor of an important and
volutionary conserved role (Goldstone et al., 2010). Of the various
yclophilins family members, CypA is important for HIV-1 infec-
ion, as demonstrated by knock out studies in human CD4+ T-cells
Braaten and Luban, 2001). Although initially it was thought that
ypA present in the producer cells and incorporated into budding 170 (2012) 15– 24 19
viruses was  critical for infection, later studies indicated that CypA
in target cells is more important, which is now the consensus in the
ﬁeld (Hatziioannou et al., 2005; Sokolskaja et al., 2004). X-ray crys-
tallography revealed that CypA binds to a loop in CA encompassing
residues 85–93 between helices 4 and 5, with residues G89 and P90
being critical for binding (Gamble et al., 1996). Importantly, when
the CA subunits are organized in a hexamer like in the native core,
the CypA-binding loop is exposed outwards on the surface, which
explains how CypA in target cells can bind to the incoming virus
(Gamble et al., 1996; Pornillos et al., 2011) (Fig. 2).
Despite intensive investigation over nearly 20 years, the precise
function of CypA in HIV-1 infection is still not known. CsA is known
to inhibit competitively CypA binding to CA and to impair the early
steps of HIV-1 infection, before or at reverse transcription (Braaten
et al., 1996b; Ptak et al., 2008; Rosenwirth et al., 1994) but the
mechanism is unclear. One possibility is that CypA promotes HIV-1
uncoating by destabilizing the viral core. CypA is a peptidyl pro-
lyl cis/trans isomerase (PPIase) that catalyses the slow cis–trans
isomerization of proline peptide (Xaa-Pro) bonds (Fischer et al.,
1989). Therefore it was hypothesized that CypA, by isomerization of
the G89-P90 bond, could change the conformation of the loop and
destabilize the core. CypA can indeed isomerize the G89–P90 bond
from cis to trans and CypA acetylation inhibits the efﬁciency of the
reaction (Bosco et al., 2002; Lammers et al., 2010), stabilizing the
bond in trans. However it is unclear what effects the isomerization
of the G89–P90 bond may have. The co-crystal structure of CypA
and CA and that of the hexameric CA ring do not provide any obvi-
ous mechanism by which subtle changes in the loop conformation
may  affect the stability of the core (Gamble et al., 1996).
An alternative hypothesis is that CypA, by binding to the loop,
may  sterically inhibit the CA–CA interactions within the hexameric
lattice forming the core. If the ratio of CA to CypA is high enough
(close to 1:1), then CA hexamers separate completely, which would
lead to the collapse of the core (Gamble et al., 1996). It is therefore
interesting to note that at a sufﬁciently high concentration, Cyp
effectively disassembles CA–NC tubes formed in vitro but has lit-
tle or no effect at lower concentrations (ratio of Cyp to CA > 1:10)
(Grattinger et al., 1999; Wiegers et al., 1999). Therefore one can
envisage a scenario whereby CypA progressively binds the incom-
ing viral core over time, until a critical point is reached (local ratio
of CypA to CA close to 1:1), CA subunits are sterically separated and
parts of the core collapse. Conversely, cis to trans isomerization of
the G89–P90 peptide might stabilize rather than de-stabilize the
core, hence CypA might exert two opposing effects on the core;
at low concentrations (in the very early stages post-entry), CypA
may  stabilize the core by promoting the cis isomerization of the
peptidyl bond but at critically high concentration it might eventu-
ally induce uncoating. According to this model, those areas of the
core that bound saturating levels of CypA would collapse whereas
other areas that bound less CypA would remain intact, ensuring a
progressive rather than a one-step uncoating event.
This scenario would explain the opposite effects of CsA observed
on core stability and the differences in the time of uncoating
observed in different cell types, which express different levels
of CypA (Arﬁ et al., 2009; Hatziioannou et al., 2005; Li et al.,
2009; Matsuoka et al., 2009). Furthermore, stabilization and de-
stabilization of the HIV-1 core by CypA may  dictate the degree of
susceptibility to restriction factors that target incoming CA such
as TRIM5 and TRIMCyp (Towers, 2007). Interestingly, whereas
mutations of residues G89 and P90 determine a loss of CypA bind-
ing to CA and compromise HIV-1 infectivity (Bukovsky et al., 1997),
other mutations in CA do not affect CypA binding yet make the virus
insensitive to CsA, and some mutations even make the virus depen-
dent on CsA for replication in a cell-type dependent way  (Aberham
et al., 1996; Braaten et al., 1996a; Yang and Aiken, 2007; Yin et al.,
1998). This suggests that CA may  be able to compensate for the
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oss of CypA binding by modulating the inter-molecular interac-
ions that stabilize the hexameric lattice. Alternatively, some CA
utants might have evolved the ability to exploit cellular factors
ther than CypA to the same end. Because CA–CypA interactions
ay  be critical for modulating the dynamics of core uncoating, they
re likely to inﬂuence downstream events of the HIV-1 life cycle.
. CA and nuclear import
Lentiviruses such as HIV-1 can infect non-dividing cells, in con-
rast to oncoretroviruses (such as MLV), which require disassembly
f the nuclear envelope during mitosis for productive infection.
his physiological property of HIV-1 is important for pathogen-
sis, given that the virus can infect non-dividing memory CD4+
-cells, macrophages and microglial cells in vivo (Freed and Martin,
001). Several viral and cellular determinants have been reported
o have an impact on active nuclear transport of HIV-1, suggesting
hat there is some redundancy or that the virus has evolved to use
everal pathways for nuclear import (Fassati, 2006). Interestingly,
A has also been implicated in HIV-1 nuclear import. The ﬁrst evi-
ence that CA inﬂuenced HIV-1 infection of non-dividing cells came
rom experiments using chimeric viruses where the Gag regions
f HIV and MLV  were swapped. If HIV-1 p17 MA was replaced
ith MLV  matrix, the resulting virus could still infect non-dividing
ells, however if p24 CA was replaced with MLV  p30 CA, then the
esulting virus could no longer infect non-dividing cells and in fact
cquired an MLV  phenotype, suggesting that CA was a dominant
eterminant (Yamashita and Emerman, 2004).
One reasonable interpretation of these results is that uncoat-
ng is different in the HIV/MLV chimera, and that MLV  CA dictates
lower uncoating, formation of a bulkier RTC/PIC, which is not able
o go across NPCs (Fassati and Goff, 1999; Yamashita and Emerman,
004). In support of this interpretation there are data showing
hat certain mutant HIV-1 CA do indeed uncoat more slowly and
ncompletely and are impaired in nuclear import (Dismuke and
iken, 2006). However HIV-1 CA may  also have a positive role in
uclear import. Several genome-wide siRNA screenings for host cell
actors implicated in HIV-1 infection identiﬁed nucleoporin (Nup)
58 (also called RanBP2), Nup153 and the nuclear transport factor
ransportin 3 (Tnpo3) (Brass et al., 2008; Konig et al., 2008). Impor-
antly, it was shown that a speciﬁc mutation in CA at position N74
etermined the ability of HIV-1 to use Nup153, Tnpo3 and, to some
xtent, also Nup358 (Lee et al., 2010). This particular mutation is
ocated at the interface between NTD and CTD interactions form-
ng the CA hexameric ring (Pornillos et al., 2009) (Fig. 1C) and was
elected by passaging HIV-1 in the presence of a dominant neg-
tive truncated form of the splicing factor CPSF6, which prevents
iral nuclear import when overexpressed in certain cell types (Lee
t al., 2010). Subsequent work conﬁrmed that Nup153 was impor-
ant for HIV-1 infection and that the viral determinant mapped to
A, however knock down of Nup153 in target cells reduced the for-
ation of 2LTR circular DNA (a hallmark of nuclear entry of the
iral genome) only partially but had a more pronounced effect on
ntegration (Matreyek and Engelman, 2011).
Tnpo3 is a member of the importin  superfamily of proteins
hat act as nuclear import or export receptors (or both) depend-
ng on whether they bind or release the cargo in the presence of
anGTP. Nuclear import receptors bind their cargos in the cyto-
lasm and release them in the nucleus upon binding to RanGTP,
hereas nuclear export receptors bind their cargos in the nucleus
n complex with RanGTP and dissociate from them in the cytoplasm
pon hydrolysis of RanGTP (Gorlich and Kutay, 1999).
Initially it was thought that Tnpo3 stimulated HIV-1 nuclear
mport by binding to IN (Christ et al., 2008; Logue et al., 2011),
owever it later became apparent that the main viral determinant 170 (2012) 15– 24
for Tnpo3 is CA and that Tnpo3 stimulates HIV-1 nuclear import
weakly. In fact Tnpo3 mainly affects post-nuclear entry steps (De
Iaco and Luban, 2011; Krishnan et al., 2010; Valle-Casuso et al.,
2012; Zhou et al., 2011) and can bind directly to the viral core
(Valle-Casuso et al., 2012; Zhou et al., 2011), more efﬁciently when
incubated in the presence of RanGTP (Zhou et al., 2011), which
suggests that Tnpo3 can act as a nuclear export receptor for CA.
Interestingly, there is evidence accumulating that Tnpo3 is also a
nuclear import factor for CPSF6, an SR-rich splicing protein (Kewal-
ramani, personal communication), and that CPSF6 binds directly to
CA within a relatively large pocket (Lee et al., 2012; Price et al.,
2012). This leads to several possible models to explain why  Tnpo3
is required for HIV-1 infection (Fig. 3). For example, lack of Tnpo3
could cause abnormal CPSF6 accumulation in the cytoplasm, where
it would bind HIV-1 CA, perturbing the viral life cycle, not too
dissimilar from a restriction factor (Kewalramani, personal com-
munication). Alternatively, CPSF6 by binding to CA could promote
some event either before or after nuclear import to facilitate HIV-1
infection (Price et al., 2012). Another model proposes that, notwith-
standing CPSF6 binding to CA, Tnpo3 is necessary to complete the
removal of any remaining CA from the viral PIC inside the nucleus
to allow efﬁcient integration (Zhou et al., 2011) (Fig. 3). This third
model will be elaborated further.
Curiously, other lentiviruses such as equine infectious anemia
virus (EIAV) and feline immunodeﬁciency virus (FIV) do not depend
on Nup153 and Tnpo3 for infection whereas SIVmac and HIV-2ROD
do (Krishnan et al., 2010; Matreyek and Engelman, 2011), conﬁrm-
ing that different lentiviruses can use different host components
for nuclear entry and post-nuclear entry events, as previously sug-
gested (Zaitseva et al., 2009).
Nup358 was  also shown to be important for HIV-1 infection in
several studies (Konig et al., 2008; Lee et al., 2010; Ocwieja et al.,
2011; Schaller et al., 2011; Zhang et al., 2010). It is a 358 kDa pro-
tein that forms long ﬁlaments protruding in the cytoplasmic side
of NPCs and it contains a Cyp-domain at its C-terminus (Wu et al.,
1995). Importantly, HIV-1 CA binds the Cyp-domain of Nup358
directly and depletion of Nup358 results in a defect of HIV-1 infec-
tivity that maps primarily at the step of nuclear import (Schaller
et al., 2011). Therefore Nup358 may  help HIV-1 dock at the nuclear
pore. The ﬂexible and ﬁlamentous nature of this nucleoporin would
seem well suited to “embrace” a large nucleoprotein complex and
retain it in close proximity of the NPC, where an appropriate reor-
ganization can take place in preparation for the actual transport
event. This mechanism implies that at least some CA remains asso-
ciated with the HIV-1 RTC/PIC until NPC docking. Nup358 might
also promote further uncoating of the viral core or even initiate
uncoating of those cores that did not disassemble in the cytoplasm
(Schaller et al., 2011) (Fig. 3). The idea that a partially disassem-
bled core reaches the NPC ﬁlaments may  also explain how certain
tRNA species, which are incorporated into the HIV-1 particle dur-
ing budding and have been shown to promote nuclear import of the
RTC/PIC, are retained within the viral complex and then exposed to
the import machinery at the right time (Zaitseva et al., 2006).
Perhaps not surprisingly, use of Nup358 is inﬂuenced by the
ability of CA to bind CypA (Schaller et al., 2011), which could be due
to the fact that the same region of CA is involved in binding to both
CypA and Nup358 and/or that CypA may  affect both the kinetics and
the degree of uncoating, and hence ultimately the need to exploit
Nup358 for infection. Indeed it is reasonable to assume that RTCs
that completed uncoating in the cytoplasm and have very little or
no CA associated may  not need Nup358 or at least may not bind to
it at the cytoplasmic side of the NPC.Consistent with this possibility, the N74D CA mutant is more
sensitive to CsA and it cannot infect macrophages efﬁciently
(Ambrose et al., 2012). This block to infection was mapped prior to
reverse transcription, suggesting that the N74D mutant uncoats too
A. Fassati / Virus Research 170 (2012) 15– 24 21
Fig. 3. Models for the multiple roles of CA in the early steps of HIV-1 infection. Shortly after entry of the HIV-1 core in the cell cytoplasm, CypA binds to CA. At low density
CypA  stabilizes the hexameric CA lattice, promoting the early steps of reverse transcription. However over time more CypA binds to the viral core until the density in certain
regions  is high (ratio CA:CypA close to 1:1) and the CA subunits in the lattice are dissociated, generating local collapse of the core structure. The process of CA disassembly
carries  on during reverse transcription, until the RTC binds to Nup358. Once the RTC/PIC docks to nuclear pores, further uncoating and other structural rearrangements occur
and  the complex is transported into the nucleus by several factors (importins, tRNAs) via an interaction with Nup153. Once inside the nucleus, residual CA, tRNAs and possibly
other  components are dissociated by Tnpo3 in complex with RanGTP. The stripped complex is now able to bind different cellular factors that are important for efﬁcient and
targeted integration into genomic DNA. The viral core can also bind to the NPC and disassemble locally, possibly using Nup358 as an uncoating factor, which replaces CypA.
Cytoplasmic CPSF6 is shown in this model to block uncoating and thus prevent nuclear import and/or integration. An alternative model proposes that CPSF6 can facilitate
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uickly and too much, making it unable to interact with Nup358,
up153 and Tnpo3.
. CA and integration
There is growing evidence indicating that CA plays a role in
ost-nuclear entry events, including integration. Certain CA muta-
ions such as N54A/N57A and Q63A/Q67A cannot infect efﬁciently
ells arrested in the cell cycle, however a careful analysis of the
tep impaired by these mutations showed that the block occurs
fter nuclear entry (Qi et al., 2008; Yamashita and Emerman, 2009;
amashita et al., 2007). These mutations are located at the inter-
ace of the NTD–NTD intermolecular CA interactions that form the
exameric ring and may  therefore change the stability of the hex-
mer itself (Pornillos et al., 2009) (Fig. 1C). Because these mutants
how defects in uncoating, it was proposed that “total uncoating
s the rate limiting step for efﬁcient infection of nondividing cells”
Yamashita et al., 2007).
A functional link between HIV-1 CA and integration has also
een described using a chemical genetic approach, which revealed
hat the small molecule Coumermycin-A1 impaired integration by
argeting HIV-1 CA (Vozzolo et al., 2010). Interestingly, the A105S
A mutation makes the virus insensitive to this block (Vozzolo et al.,
010) and at the same time makes it independent of Tnpo3 for infec-
ion, suggesting that Coumermycin-A1 and lack of Tnp3 perturb the
ame pathway. The presence of CA associated with the HIV-1 PIC
nside the nucleus can also be inferred from genetic studies in whichetely dissociate CA at an early stage must presumably use a different pathway that
the restriction factors Fv-1 and members of the TRIM protein family
were fused to CypA. The resulting fusion proteins maintained their
speciﬁc ability to bind CA yet restricted HIV-1 at a post-nuclear
entry step (Schaller et al., 2007; Yap et al., 2006). Furthermore,
certain CA mutations, including N74D, show a different integra-
tion pattern in host chromosomes compared to wild type virus,
which can also be observed upon depletion of Tnpo3 and Nup358
(Ocwieja et al., 2011; Schaller et al., 2011). Lastly, small amounts
of CA could be detected in the nuclei of acutely infected cells by
immunoﬂuorescence and cell fractionation approaches (Zhou et al.,
2011).
All the above evidence argues in favor of a link between CA,
integration efﬁciency and integration targeting, therefore it is
conceivable that “total uncoating” can happen in the nuclei, par-
ticularly in cells arrested in the cell cycle where normal uncoating
might be less efﬁcient or slower. In agreement with this possibility,
Tnpo3 was shown to promote uncoating in the nucleus of infected
cells by acting as an export factor for CA and certain tRNAs species
(Zhou et al., 2011). Once the viral complex has translocated across
NPCs, Tnpo3 would act as an export factor for residual CA and other
elements bound to the complex, and by displacing these elements
it would favor binding of other host factors present in the nucleus
critical for efﬁcient and targeted integration. This would occur
only in the presence of RanGTP inside the nuclei. Hence Tnpo3
would orchestrate a relay race where different host factors bind to
and are released from the HIV-1 RTC/PIC in a regulated and timely
manner until its ﬁnal destination is reached. The RanGDP/RanGTP
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radient across the nuclear envelope would ensure that host
actors are interchanged in the right compartment (Fig. 3). On the
ther hand, mutant viruses that uncoat too fast or too completely,
r cannot bind certain host factors, would not follow this pathway
nd therefore would become independent of Nup358, Nup153
nd Tnpo3. Their RTC/PICs would presumably be in a different
onformation, unable to bind the required host factors and hence
ould integrate into different genomic regions.
. Small compounds targeting CA
Given the multiple and important roles of CA in the early steps
f HIV-1 infection, signiﬁcant efforts are being made to develop
mall compounds that can interfere with CA function. In fact several
ompounds and peptides binding to CA have been shown to perturb
iral particle assembly and maturation (Jin et al., 2010; Lemke et al.,
012; Sticht et al., 2005; Tang et al., 2003). Remarkably, compounds
hat bind to the same pocket in CA but have a slightly different
hemical structure can have different effects, such as inhibiting
ssembly or maturation, underlying the tight functional organiza-
ion of the CA lattice (Lemke et al., 2012). In addition to compounds
hat block the late stages of the viral life cycle, more recently three
ompounds have been reported to inhibit early replication stages
y targeting CA. Compound PF-74 was developed by Pfeizer start-
ng from a high through put screening for inhibitors of HIV-1 and it
inds to a preformed pocket in the CA NTD delimited by helices 3,
, 5 and 7 (Blair et al., 2010). PF-74 affects primarily early reverse
ranscription, presumably by de-stabilizing the core prematurely
hrough a loosening of the NTD–CTD intermolecular CA interac-
ions or by preventing some host factor such as CPSF6 to bind the
ncoming core (Blair et al., 2010; Price et al., 2012; Shi et al., 2011).
F-74 also inhibits late stages of the HIV-1 life cycle by perturbing
ormation of the typical mature conical core (Blair et al., 2010). At
he same time PF-74 was developed, Coumermycin-A1, an antibi-
tic originally developed by Roche, was also shown to inhibit HIV-1
ntegration by targeting CA (Vozzolo et al., 2010) and molecular
ocking indicated that this compound binds to an extended pocket
n the NTD CA, which includes the PF-74 binding pocket (Zhou et al.,
n preparation). Therefore, similarly to other compounds recently
escribed (Lemke et al., 2012), PF-74 and Coumermycin-A1 bind
o the same CA region but appear to have different effects. Inter-
stingly, the antiviral activity of both PF-74 and Coumermycin-A1
s positively modulated by CypA, which reinforces the view that
hese drugs impact on core uncoating (Shi et al., 2011; Vozzolo
t al., 2010). Another series of small compounds binding to a dif-
erent pocket of the NTD CA has been described, also impairing
ainly reverse transcription (Kortagere et al., 2012). These results
how that CA is indeed a promising target for drug development
nd suggest the possibility that even small differences in the chem-
cal structure of the compounds might lead to alternative ways to
lock HIV-1 infection. One important question concerns the genetic
arrier to these compounds and how difﬁcult will be for viruses to
scape the effects of such drugs. Nonetheless, it is an area of much
nterest and promise.
. Concluding remarks
In conclusion, it is becoming increasingly apparent that CA
as multiple roles during the early stages of HIV-1 infection. CA
inks into intrinsic and innate immune recognition, nuclear import
nd integration and may  bind to host cell factors that directly or
ndirectly inﬂuence such events. Using a combination of genetic,
iochemical and imaging approaches, new aspects of HIV-1 biology
re being discovered, which will illuminate important cellular path-
ays and will lead to the development of new small molecules with 170 (2012) 15– 24
therapeutic potential. Many questions remain, for example if there
are additional roles for Nup153, Nup358 and Tnpo3 in HIV-1 infec-
tion, if additional host cell factors or restriction factors that bind
CA are involved in the early steps of HIV-1 infection, how PF-74,
Coumermycin A1 and other small compounds work, what is their
relationship with CypA, why the phenotype of several CA mutants
is cell-type dependent and what is the impact of these factors on
HIV-1 transmission and the natural history of HIV-1 infection. We
are still in the early days of the early steps of HIV-1 infection!
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